NO994850L - Farmakologiske midler - Google Patents

Farmakologiske midler

Info

Publication number
NO994850L
NO994850L NO994850A NO994850A NO994850L NO 994850 L NO994850 L NO 994850L NO 994850 A NO994850 A NO 994850A NO 994850 A NO994850 A NO 994850A NO 994850 L NO994850 L NO 994850L
Authority
NO
Norway
Prior art keywords
pharmacological agents
glurs
selective
antagonists
receptor
Prior art date
Application number
NO994850A
Other languages
English (en)
Other versions
NO994850D0 (no
Inventor
David Bleakman
David R Helton
David Lodge
Smriti Iyengar
Paul L Ornstein
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO994850D0 publication Critical patent/NO994850D0/no
Publication of NO994850L publication Critical patent/NO994850L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Antagonister som er selektive for GluRS-reseptoren er brukbar for behandling av smerte. Også oppdaget er nye dekahydroisoquinolinderivater, som er selektive GluRS-reseptor- antagonister.
NO994850A 1997-04-07 1999-10-05 Farmakologiske midler NO994850L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4279597P 1997-04-07 1997-04-07
PCT/US1998/006905 WO1998045270A1 (en) 1997-04-07 1998-04-06 Pharmacological agents

Publications (2)

Publication Number Publication Date
NO994850D0 NO994850D0 (no) 1999-10-05
NO994850L true NO994850L (no) 1999-10-05

Family

ID=21923795

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994850A NO994850L (no) 1997-04-07 1999-10-05 Farmakologiske midler

Country Status (17)

Country Link
US (1) US6242462B1 (no)
EP (1) EP0980358A4 (no)
JP (1) JP2001521505A (no)
KR (1) KR20010006075A (no)
CN (1) CN1259126A (no)
AU (1) AU734657B2 (no)
BR (1) BR9809071A (no)
CA (1) CA2285192A1 (no)
EA (1) EA199900912A1 (no)
HU (1) HUP0002030A3 (no)
ID (1) ID23013A (no)
IL (1) IL132086A0 (no)
NO (1) NO994850L (no)
NZ (1) NZ337827A (no)
PL (1) PL336068A1 (no)
TR (1) TR199902449T2 (no)
WO (1) WO1998045270A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60002733T2 (de) 1999-07-06 2004-03-18 Eli Lilly And Co., Indianapolis Diester prodrugs von decahydroischinoline-3-carbonsäure
DZ3209A1 (fr) 1999-07-06 2001-01-11 Lilly Co Eli Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine.
AU2574801A (en) 1999-12-22 2001-07-03 Eli Lilly And Company Selective iGLUR5 receptor antagonists
WO2002053139A2 (en) * 2001-01-05 2002-07-11 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
US6855725B2 (en) 2001-01-05 2005-02-15 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO2002053555A2 (en) 2001-01-05 2002-07-11 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
CN100548299C (zh) * 2001-01-05 2009-10-14 伊莱利利公司 兴奋性氨基酸受体拮抗剂
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO2002058691A1 (en) * 2001-01-23 2002-08-01 Neurosearch A/S Use of non-competitive and selective glur5 antagonists as glutamate receptor modulating compounds
PT1511741E (pt) 2002-04-26 2013-02-05 Lilly Co Eli Derivados éster de um ácido deca-hidroisoquinolino-3- carboxílico como analgésicos
WO2005007106A2 (en) * 2003-07-10 2005-01-27 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a non-nmda glutamate modulator for the treatment of central nervous system damage
JP4964593B2 (ja) * 2003-09-25 2012-07-04 セノメド バイオサイエンシーズ，エルエルシー 神経学的病状の治療用のテトラヒドロインドロン誘導体
US20050107439A1 (en) * 2003-11-10 2005-05-19 Helton David R. Composition and method for treating emesis
DK2083811T3 (en) 2006-11-22 2017-01-30 Clinical Res Ass Llc PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM
EP2150248A4 (en) 2007-01-16 2011-06-29 Univ Johns Hopkins GLUTAMATE RECEPTOR ANTAGONISTS AND METHOD OF USE
WO2009062134A1 (en) * 2007-11-09 2009-05-14 Cenomed Biosciences, Llc Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
KR101746944B1 (ko) * 2015-09-23 2017-06-14 주식회사 포스코 도장 선영성이 우수한 도금강판의 제조방법 및 이에 의해 제조된 도금강판

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5446051A (en) * 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
ATE204852T1 (de) * 1995-02-15 2001-09-15 Bearsden Bio Inc Alkylcarboxy-aminosäure modulatoren für den kainat-rezeptor

Also Published As

Publication number Publication date
EA199900912A1 (ru) 2000-04-24
CN1259126A (zh) 2000-07-05
KR20010006075A (ko) 2001-01-15
AU6955598A (en) 1998-10-30
WO1998045270A1 (en) 1998-10-15
PL336068A1 (en) 2000-06-05
NO994850D0 (no) 1999-10-05
AU734657B2 (en) 2001-06-21
NZ337827A (en) 2000-12-22
IL132086A0 (en) 2001-03-19
CA2285192A1 (en) 1998-10-15
JP2001521505A (ja) 2001-11-06
HUP0002030A3 (en) 2002-01-28
ID23013A (id) 1999-12-30
HUP0002030A2 (hu) 2001-04-28
EP0980358A1 (en) 2000-02-23
BR9809071A (pt) 2000-08-01
EP0980358A4 (en) 2001-02-07
TR199902449T2 (xx) 2000-07-21
US6242462B1 (en) 2001-06-05

Similar Documents

Publication Publication Date Title
EA199900912A1 (ru) Фармацевтические средства
DK1208095T3 (da) Dibenzopyraner som glucocorticoidreceptorantagonister til behandling af diabetes
EE200200355A (et) EP4 retseptori selektiivsed agonistid osteoporoosi raviks
DK0806952T3 (da) Progesteronantagonister til fremstillingen af lægemidler til behandling af dysfunktionelle uterine blødninger
BR0010215A (pt) Derivados de indolina como antagonistas de progesterona
EA199700156A1 (ru) Производные индола как антагонисты рецептора 5-нт
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
NO20032360D0 (no) EP4 reseptor selektive agonister for behandling av osteoporose
PT1349839E (pt) Derivados de feniletenilo ou feniletinilo como antagonistas do receptor de glutamato
DK0901470T3 (da) Indolderivater egnede som endothelinreceptorantagonister
NO20016246D0 (no) Selektiv iGluR5 reseptorantagonist for behandling av migrene
NO20034122D0 (no) Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte
IT1307900B1 (it) Antagonisti iii del recettore ccr-3.
NO20020574D0 (no) Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden
NO993350L (no) Vitronectin-reseptor-antagonister
IT1308657B1 (it) Antagonisti ii del recettore ccr-3.
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
NO20002217L (no) Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler
TR200002896T2 (tr) Kalsilitik Bileşimler
ATE245156T1 (de) Aryl-annellierte disubstituierte pyridine : nk3 rezeptor-liganden
TR199700956T1 (xx) Indazolkarboksamidler.
DK0983275T3 (da) Nye triptolidderivater, der er nyttige til behandling af autoimmune sygdomme
NO20014855L (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
DK0912556T3 (da) Indolinderivater, der er anvendelige som 5-HT-2C-receptorantagonister
EE9700309A (et) AII-retseptori antagonistide uus farmakoloogiline kasutus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application